LEADER 01074nam0-22003251i-450- 001 990001818690403321 005 20090508134214.0 035 $a000181869 035 $aFED01000181869 035 $a(Aleph)000181869FED01 035 $a000181869 100 $a20030910d1970----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $aAcque pulite$fAssociazione nazionale delle bonifiche delle irrigazioni e dei miglioramenti fondiari 210 $aRoma$cAssociazione Nazionale delle Bonifiche delle Irrigazioni e dei Miglioramenti Fondiari$d1970 215 $ap. 515-735$d24 cm 300 $aLa Bonifica, 24(11-12): 515-735, numero speciale 610 0 $aInquinamento idrico 610 0 $aAcqua 676 $a363.739 4 710 02$aAssociazione nazionale delle bonifiche, delle irrigazioni e dei miglioramenti fondiari$031202 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001818690403321 952 $a60 DONO SARLI 46$b7139$fFAGBC 959 $aFAGBC 996 $aAcque pulite$9412710 997 $aUNINA LEADER 02873nam0 2200517 i 450 001 VAN0105340 005 20230801115705.160 017 70$2N$a9783319193397 100 $a20160503d2015 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aRandom walks, random fields, and disordered systems$fAnton Bovier ... [et al.]$gMarek Biskup, Ji?í Cerný, Roman Kotecký editors 210 $aCham [etc.]$cSpringer$d2015 215 $aXIII, 239 p.$cill.$d24 cm 461 1$1001VAN0102250$12001 $aLecture notes in mathematics$1210 $aBerlin [etc.]$cSpringer$v2144 500 1$3VAN0234151$aRandom walks, random fields, and disordered systems$91388116 606 $a60K35$xInteracting random processes; statistical mechanics type models; percolation theory [MSC 2020]$3VANC019993$2MF 606 $a60-XX$xProbability theory and stochastic processes [MSC 2020]$3VANC020428$2MF 606 $a82B41$xRandom walks, random surfaces, lattice animals, etc. in equilibrium statistical mechanics [MSC 2020]$3VANC020793$2MF 606 $a82D30$xStatistical mechanical studies of random media, disordered materials (including liquid crystals and spin glasses) [MSC 2020]$3VANC021482$2MF 606 $a82B26$xPhase transitions (general) in equilibrium statistical mechanics [MSC 2020]$3VANC023338$2MF 606 $a00-XX$xGeneral and overarching topics; collections [MSC 2020]$3VANC025238$2MF 606 $a60K05$xRenewal theory [MSC 2020]$3VANC026575$2MF 606 $a82B28$xRenormalization group methods in equilibrium statistical mechanics [MSC 2020]$3VANC028645$2MF 606 $a60J85$xApplications of branching processes [MSC 2020]$3VANC030764$2MF 606 $a05D40$xProbabilistic methods in extremal combinatorics, including polynomial methods (combinatorial Nullstellensatz, etc.) [MSC 2020]$3VANC032313$2MF 610 $aCavity Method$9KW:K 610 $aDisordered Systems$9KW:K 610 $aLoop-Soup Model$9KW:K 610 $aRandom Walks$9KW:K 610 $aRandom fields$9KW:K 620 $aCH$dCham$3VANL001889 702 1$aBiskup$bMarek$3VANV056028 702 1$aBovier$bAnton$3VANV046531 702 1$aCerný$bJi?í$3VANV081957 702 1$aKotecký$bRoman$3VANV081958 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20240614$gRICA 856 4 $uhttps://doi.org/10.1007/978-3-319-19339-7$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$1IT-CE0120$2VAN08 912 $fN 912 $aVAN0105340 950 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$d08CONS e-book $e08LNM2144 20160503 996 $aRandom walks, random fields, and disordered systems$91388116 997 $aUNICAMPANIA LEADER 04444nam 22006975 450 001 9910300333103321 005 20200707022356.0 010 $a3-642-45195-0 024 7 $a10.1007/978-3-642-45195-9 035 $a(CKB)3710000000089195 035 $a(EBL)1698373 035 $a(OCoLC)881161842 035 $a(SSID)ssj0001166514 035 $a(PQKBManifestationID)11657049 035 $a(PQKBTitleCode)TC0001166514 035 $a(PQKBWorkID)11121117 035 $a(PQKB)10365258 035 $a(MiAaPQ)EBC1698373 035 $a(DE-He213)978-3-642-45195-9 035 $a(PPN)176750177 035 $a(EXLCZ)993710000000089195 100 $a20140215d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aProstate Cancer Prevention /$fedited by Jack Cuzick, Mangesh A. Thorat 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (167 p.) 225 1 $aRecent Results in Cancer Research,$x0080-0015 ;$v202 300 $aDescription based upon print version of record. 311 $a3-642-45194-2 320 $aIncludes bibliographical references. 327 $aBiology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers ? CCP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers ? PCA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5? reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications. 330 $aProstate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5?-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers. 410 0$aRecent Results in Cancer Research,$x0080-0015 ;$v202 606 $aOncology 606 $aUrology 606 $aCancer$xResearch 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aUrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H62002 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 615 0$aOncology. 615 0$aUrology. 615 0$aCancer$xResearch. 615 14$aOncology. 615 24$aUrology. 615 24$aCancer Research. 676 $a616.99463 686 $aXH 2200$2rvk 702 $aCuzick$b Jack$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aThorat$b Mangesh A$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300333103321 996 $aProstate Cancer Prevention$91522993 997 $aUNINA